227 related articles for article (PubMed ID: 23135613)
21. Use of intravenous immunoglobulin to treat chronic bilateral otomastoiditis in the setting of rituximab induced hypogammaglobulinemia.
Otremba MD; Adam SI; Price CC; Hohuan D; Kveton JF
Am J Otolaryngol; 2012; 33(5):619-22. PubMed ID: 22361345
[TBL] [Abstract][Full Text] [Related]
22. B-cell therapies for rheumatoid arthritis.
Scher JU
Bull NYU Hosp Jt Dis; 2012; 70(3):200-3. PubMed ID: 23259629
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic effectiveness of minimal doses of rituximab in a patient with rheumatoid arthritis.
Bruzzese V
Int J Immunopathol Pharmacol; 2011; 24(1):265-7. PubMed ID: 21496414
[TBL] [Abstract][Full Text] [Related]
24. Reactivation of hepatitis virus B infection in a patient with rheumatoid arthritis after treatment with rituximab.
Salman-Monte TC; Lisbona MP; García-Retortillo M; Maymó J
Reumatol Clin; 2014; 10(3):196-7. PubMed ID: 24054835
[No Abstract] [Full Text] [Related]
25. [Rituximab treatment of rheumatoid arthritis: new evidence].
Nasonov EL
Ter Arkh; 2009; 81(6):82-91. PubMed ID: 19663200
[TBL] [Abstract][Full Text] [Related]
26. Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis.
Mishra R; Singh V; Pritchard CH
Rheumatol Int; 2011 Apr; 31(4):481-4. PubMed ID: 20091035
[TBL] [Abstract][Full Text] [Related]
27. B-cell therapies in established rheumatoid arthritis.
Leandro MJ; Becerra-Fernandez E
Best Pract Res Clin Rheumatol; 2011 Aug; 25(4):535-48. PubMed ID: 22137923
[TBL] [Abstract][Full Text] [Related]
28. [Consensus on the Use of Rituximab in Rheumatoid Arthritis. A document with evidence-based recommendations. Grupo de Expertos en Rituximab. ].
Martín Mola E; Hernández B; García-Arias M; Alvaro-Gracia JM; Balsa A; Reino JG; Marenco de la Fuente JL; Martínez-Taboada V; Ivorra JA; Sanmartí R;
Reumatol Clin; 2011; 7(1):30-44. PubMed ID: 21794777
[TBL] [Abstract][Full Text] [Related]
29. Rheumatoid arthritis, alveolar echinococcosis, and rituximab: a case report.
Dentan C; Mazet R; Gilson M; Marchou-Lopez S; Gaudin P
Joint Bone Spine; 2012 May; 79(3):325-7. PubMed ID: 22154698
[No Abstract] [Full Text] [Related]
30. Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: results from the GISEA register.
Sebastiani M; Anelli MG; Atzeni F; Bazzani C; Farina I; Fedele AL; Favalli EG; Fineschi I; Cino N; Dal Forno I; Gasparini S; Cassarà E; Giardina R; Bruschi E; Addimanda O; Cassone G; Lopriore S; Sarzi-Puttini P; Filippini M; Pignatti F; Gremese E; Biggioggero M; Manganelli S; Amato G; Caimmi C; Salaffi F; Iannone F; Ferri C; Sandri G; Lapadula G; Gorla R; Govoni M; Ferraccioli G; Marchesoni A; Galeazzi M; Foti R; Carletto A; Cantini F; Triolo G; Epis OM; Salvarani C;
Joint Bone Spine; 2014 Dec; 81(6):508-12. PubMed ID: 25082646
[TBL] [Abstract][Full Text] [Related]
31. [Rituximab in patients with rheumatoid arthritis: systematic review].
Brodszky V; Czirják L; Géher P; Hodinka L; Kárpáti K; Péntek M; Poór G; Szekanecz Z; Gulácsi L
Orv Hetil; 2007 Oct; 148(40):1883-93. PubMed ID: 17905683
[TBL] [Abstract][Full Text] [Related]
32. B cell-targeted therapy for rheumatoid arthritis: an update on the evidence.
Looney RJ
Drugs; 2006; 66(5):625-39. PubMed ID: 16620141
[TBL] [Abstract][Full Text] [Related]
33. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients.
van Vollenhoven RF; Emery P; Bingham CO; Keystone EC; Fleischmann RM; Furst DE; Tyson N; Collinson N; Lehane PB
Ann Rheum Dis; 2013 Sep; 72(9):1496-502. PubMed ID: 23136242
[TBL] [Abstract][Full Text] [Related]
34. What is the role of rituximab in the treatment of rheumatoid arthritis?
Atzeni F; Doria A; Turiel M; Sarzi-Puttini P
Autoimmun Rev; 2007 Sep; 6(8):553-8. PubMed ID: 17854748
[TBL] [Abstract][Full Text] [Related]
35. Cytomegalovirus colitis and hypo-IgG after rituximab therapy for rheumatoid arthritis.
Vallet H; Houitte R; Azria A; Mariette X
J Rheumatol; 2011 May; 38(5):965-6. PubMed ID: 21532065
[No Abstract] [Full Text] [Related]
36. A case of tumour necrosis factor-α inhibitor- and rituximab-induced plantar pustular psoriasis that completely resolved with tocilizumab.
Jayasekera P; Parslew R; Al-Sharqi A
Br J Dermatol; 2014 Dec; 171(6):1546-9. PubMed ID: 24890762
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of rituximab in elderly patients with rheumatoid arthritis enrolled in a French Society of Rheumatology registry.
Payet S; Soubrier M; Perrodeau E; Bardin T; Cantagrel A; Combe B; Dougados M; Flipo RM; Le Loët X; Shaeverbeke T; Ravaud P; Gottenberg JE; Mariette X
Arthritis Care Res (Hoboken); 2014 Sep; 66(9):1289-95. PubMed ID: 25299001
[TBL] [Abstract][Full Text] [Related]
38. Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis.
Chan CY; Browning JC; Larsen F; Hsu S
Dermatol Online J; 2008 Sep; 14(9):12. PubMed ID: 19061594
[TBL] [Abstract][Full Text] [Related]
39. Letter: A case of generalized guttate psoriasis induced by etanercept with relapse after abatacept.
Brigant F; Clavel G; Chatelain D; Lok C; Chaby G
Dermatol Online J; 2011 Jun; 17(6):11. PubMed ID: 21696691
[TBL] [Abstract][Full Text] [Related]
40. B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience.
Shaw T; Quan J; Totoritis MC
Ann Rheum Dis; 2003 Nov; 62 Suppl 2(Suppl 2):ii55-9. PubMed ID: 14532151
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
